In the news.
- 2026
The Hillman Letter launches on Substack
New publication on FDA regulatory strategy, frontier therapeutics, and capital decisions in healthcare. Read at thehillmanletter.substack.com.
- 2026
Hillman Ventures marks 30 years of frontier biotech investing
The private family office founded in Dallas in 1995 continues its focus on inflammation, damaged tissue, and tumor-based cancer platforms grounded in FDA biologics pathway thinking.
- 2026
FixCancer.org launches public-facing TOL site
Targeted Osmotic Lysis explainer and mechanism walkthrough goes live. TOL is investigational, is not FDA-approved, and has no registered clinical trial. See
fixcancer.org.
Andrew Hillman Scholarship for Entrepreneurs
A scholarship in development to support undergraduate students with demonstrated entrepreneurial ambition. Details to be announced.
Andrew Hillman Grant for Biotech
A grant in development to support work at the intersection of biotechnology and translational medicine. Details to be announced.